These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 29373183)

  • 1. B-Natriuretic Peptide Pathway Modulation for the Management of Heart Failure With Reduced Ejection Fraction.
    Renew JR; Cyrille N; Elyahu AY; Ramakrishna H
    J Cardiothorac Vasc Anesth; 2018 Jun; 32(3):1500-1506. PubMed ID: 29373183
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial: (New drug (LCZ696) for the treatment of heart failure with reduced ejection fraction after 10 years. Can one study change the guidelines?).
    Athyros VG; Katsiki N; Karagiannis A
    Curr Vasc Pharmacol; 2014; 12(6):867-9. PubMed ID: 25516014
    [No Abstract]   [Full Text] [Related]  

  • 3. First-in-class angiotensin receptor neprilysin inhibitor in heart failure.
    Vardeny O; Tacheny T; Solomon SD
    Clin Pharmacol Ther; 2013 Oct; 94(4):445-8. PubMed ID: 23872864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Review of New Pharmacologic Treatments for Patients With Chronic Heart Failure With Reduced Ejection Fraction.
    Nguyen E; Weeda ER; White CM
    J Clin Pharmacol; 2016 Aug; 56(8):936-47. PubMed ID: 26626162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-Analysis of Efficacy of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction.
    Salah HM; Fudim M; Al'Aref SJ; Khan MS; Almarzooq ZI; Devabhaktuni SR; Mentz RJ; Butler J; Greene SJ
    Am J Cardiol; 2021 Apr; 145():165-168. PubMed ID: 33529619
    [No Abstract]   [Full Text] [Related]  

  • 7. First-in-Class Composite Angiotensin Receptor-Neprilysin Inhibitors (ARNI) in Practice.
    Barghash MH; Desai AS
    Clin Pharmacol Ther; 2017 Aug; 102(2):265-268. PubMed ID: 28512738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study.
    Zile MR; Jhund PS; Baicu CF; Claggett BL; Pieske B; Voors AA; Prescott MF; Shi V; Lefkowitz M; McMurray JJ; Solomon SD;
    Circ Heart Fail; 2016 Jan; 9(1):. PubMed ID: 26754625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Novel Treatment Approaches for Heart Failure With Reduced Ejection Fraction.
    Patel S; Veltri K
    J Pharm Pract; 2017 Oct; 30(5):541-548. PubMed ID: 27194070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential Uses of Sacubitril/Valsartan: Need for Data on Efficacy and Safety.
    Huet F; Akodad M; Kalmanovitch E; Adda J; Agullo A; Batistella P; Roubille C; Roubille F
    Am J Cardiovasc Drugs; 2019 Feb; 19(1):1-10. PubMed ID: 30345485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs.
    Gori M; Volterrani M; Piepoli M; Senni M
    Int J Cardiol; 2017 Jan; 226():136-140. PubMed ID: 27378659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The PARAGON Heart Failure trial - ongoing investigation of the angiotensin receptor antagonist/neprilysin inhibitor sacubitril/valsartan in heart failure patients with hypertension and preserved ejection fraction.
    Kjeldsen SE; Narkiewicz K; Burnier M; Oparil S
    Blood Press; 2019 Aug; 28(4):215-216. PubMed ID: 31184508
    [No Abstract]   [Full Text] [Related]  

  • 13. Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review.
    King JB; Bress AP; Reese AD; Munger MA
    Pharmacotherapy; 2015 Sep; 35(9):823-37. PubMed ID: 26406774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
    Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
    Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: lessons from randomized controlled trials and registries.
    Rossignol P; Zannad F; Pitt B;
    Int J Cardiol; 2014 Dec; 177(3):731-3. PubMed ID: 25465821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sacubitril/Valsartan: The Newest Addition to the Toolbox for Guideline-Directed Medical Therapy of Heart Failure.
    Rodgers JE
    Am J Med; 2017 Jun; 130(6):635-639. PubMed ID: 28285069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.
    Jhund PS; Claggett B; Packer M; Zile MR; Voors AA; Pieske B; Lefkowitz M; Shi V; Bransford T; McMurray JJ; Solomon SD
    Eur J Heart Fail; 2014 Jun; 16(6):671-7. PubMed ID: 24692284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: sacubitril/valsartan.
    Chrysant SG
    J Am Soc Hypertens; 2017 Jul; 11(7):461-468. PubMed ID: 28652105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-Hospital Initiation of Angiotensin Receptor-Neprilysin Inhibitors-The Time Is Now.
    Srivastava PK; Fonarow GC
    JAMA Cardiol; 2019 Mar; 4(3):195-196. PubMed ID: 30810709
    [No Abstract]   [Full Text] [Related]  

  • 20. Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan.
    Hsiao FC; Wang CL; Chang PC; Lu YY; Huang CY; Chu PH
    J Cardiovasc Pharmacol Ther; 2020 Mar; 25(2):152-157. PubMed ID: 31514513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.